ArticleJournal of psoriasis and psoriatic arthritis2019
TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.
Article in Journal of psoriasis and psoriatic arthritis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review.Rheumatology international · 2024Pooled it
- Pooled it
- The molecular mechanism of the adverse effects of the biological and small molecular drugs in the therapy of inflammatory skin diseases - psoriasis and atopic dermatitis.Annals of medicine · 2026Review
- Tip-retained hydrated silk fibroin microneedles for sustained local delivery of TNF-α antagonist in psoriasis treatment.International journal of pharmaceutics: X · 2026Article
- Two case reports of medication-induced elkonyxis in adolescents and literature review.JAAD case reports · 2026Article
- Risk factors for cutaneous complications of advanced therapies in paediatric inflammatory bowel disease patients.Pediatric research · 2026Article
- Dual-Site Inflammation During Adalimumab Therapy: Birdshot Chorioretinopathy Complicated by Paradoxical Psoriasis.Cureus · 2026Article
- Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities.Inflammopharmacology · 2026Review
- Review
- Disproportionality analysis highlights paradoxical psoriasis as a clinically significant class effect of tumor necrosis-α inhibitors in pediatric populations.Pediatric research · 2026Article
- Special Issue: The Role of Cytokines in Disease.International journal of molecular sciences · 2026Article
- The overlooked surface: cutaneous manifestations of inflammatory bowel disease.Translational gastroenterology and hepatology · 2026Review
- The cutaneous mirror: leveraging drug-induced skin phenotypes as early visual risk signals for systemic toxicity, a comprehensive review.Frontiers in drug safety and regulation · 2026Review
- Male sexual dysfunction associated with TNF-α inhibitors: an indication-stratified global pharmacovigilance analysis.Frontiers in pharmacology · 2026Article
- Tannic acid inhibits TNF-α signaling by targeting the protein disulfide isomerase and alleviates symptoms in an imiquimod-induced psoriasis mouse model.Cell communication and signaling : CCS · 2025Article
- Paradoxical pustular psoriasis induced by tumor necrosis factor inhibitor with elevated interferon-alpha in an ankylosing spondylitis patient: A case report.JAAD case reports · 2025Article
- PIEZO1 promotes psoriasis-like skin inflammation in mice via NF-κB/IL-17 signaling pathway activation.Molecular medicine (Cambridge, Mass.) · 2025Article
- Prevalence of inflammatory skin disorders in patients with inflammatory bowel disease (IBD).Archives of dermatological research · 2025Article
- The Role of Diet in Modulating Inflammation and Oxidative Stress in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis.Nutrients · 2025Review
- Thermo-responsive methylcellulose/hyaluronic acid-mesalamine hydrogel in targeted drug delivery for ulcerative colitis.RSC advances · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Tumor necrosis factor a (TNF-α)-targeted therapies have expanded the therapeutic options for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA) and have significantly improved patients' quality of life. Paradoxically, anti-TNF-α agents may induce psoriatic eruptions or worsen preexisting psoriatic skin disease. Currently, there is no standard approach for the management of TNF inhibitor-induced psoriasis. Here, we conduct a literature review on TNF inhibitor-induced psoriasis and introduce a novel treatment algorithm for maintaining otherwise effective anti-TNF therapy versus switching to a different class as appropriate in the management of patients with IBD, RA, psoriasis, or PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.